Palatin Announces Positive Results In Phase IIb Study Of Bremelanotide In Diabetic Nephropathy

(RTTNews) - Palatin Technologies, Inc. (PTN), Thursday announced positive data from phase IIb BREAKOUT study, evaluating Bremelanotide in patients with confirmed Type 2 diabetic nephropathy, the most common form of chronic kidney disease.

At six months, 71 percent of participants achieved over 30 percent reduction in the urine protein to creatinine ratio, and 71 percent achieved improved or stabilized estimated glomerular filtration rate.

The therapy also increased urinary vascular endothelial growth factor levels in 37.5 percent of participants and reduced urinary synaptopodin losses in 36 percent.

During the pre-market hours, Palatin's stock is trading at $0.78, up 4.37 percent on the New York Stock Exchange.